Bentham Science Logo

Technology Transfer and Entrepreneurship

Volume 6, 2 Issues, 2019
ISSN: 2213-8102 (Online)
ISSN: 2213-8099 (Print)
This journal supports open access

Peer Review Workflow

Evaluation of manuscripts is carried out by the journal’s Editors and the invited external peer reviewers according to the following procedures.

The editorial process and peer-review workflow for each journal are taken care of by a team of Senior Editors, Editorial Board Members (EABMs) who have expertise in their specific fields and the publication managers. Bentham follows a single blind peer review process. The services of Senior Editors and Editorial Board Members are sought through invitations to organize and conduct the peer-review of a submitted manuscript, keeping in view the scope of the manuscript and the expertise of Editors. Manuscripts are forwarded for evaluation to Editors initially and then subsequently to independent external reviewers to check if the research work presented in the manuscript:

  1. falls within the scope of the journal and
  2. meets the editorial criteria of Bentham Science Publishers in terms of originality and quality.

Editors may recommend the acceptance or rejection of a manuscript by conducting the peer review themselves, based on their own knowledge and experience, or they may take assistance and advice from other experts in the field.

After review of the manuscript by at least two independent experts, in addition to the views of the Editors, the decision is relayed to the authors, which may be categorized as:

  • Accept without changes
  • Revisions Required
  • Reject

Selection of Reviewers

The Editor-in-Chief (EiC) and Senior Editors of a journal together with the publication manager have the right to select reviewers for a particular manuscript considering the knowledge and experience of the reviewers.

Before sending the manuscripts to a reviewer, Bentham Science seeks consent from potential reviewers about their availability and willingness to carry out a review. The correspondence between the editorial office of the journal and reviewers is kept strictly confidential. The author does not know who has conducted the review on his or her manuscript.

Purpose of A Review

A review report provides the Editor-in-Chief/Senior Editor with an expert opinion on the quality of the manuscript under consideration. It also supplies authors with explicit feedback on how to improve their papers to make them acceptable for publication in the journal. Although confidential comments to the editors are not relayed to authors, any remarks that may help improve the quality of the manuscript are forwarded to the authors for their consideration. A good review report answers the following important areas:

  • Is the work novel and of high standards?
  • What are the main findings of the paper? Is relevant work of other authors in the field appropriately acknowledged and references given to the previous literature?
  • Do the experimental data support the declarations? If not, what other evidence may prove fruitful?
  • What kind of readers would benefit from the manuscript and why?
  • In what further directions would it be feasible to take the current research?

Important Points to Consider

Reviewers are expected to provide advice on the following points in their review reports:

  • Is the manuscript written comprehensively enough to be understandable? If not, how could it be improved?
  • Have adequate proofs been provided for the declarations?
  • Have the authors addressed the previous findings fairly?
  • Does the paper offer enough details of its methodology to reproduce the experiments?
  • Bentham Science encourages authors to publish detailed protocols as supporting information online. Do any particular methods used in the manuscript warrant such a protocol?

Privacy Statement

The peer-review of a manuscript is a confidential process. Reviewers should keep the whole process completely confidential. They should consult the EiC/Senior Editor and obtain permission before consulting another colleague for help in the peer-review of the submitted manuscript.

Reviewers should not disclose any information whatsoever to anyone before publication of the manuscript.

Prompt Review

The reviewers are expected to provide their reports in a timely fashion since a prompt review leads to the timely publication of a manuscript which is beneficial not only for the authors but for the scientific community as well.

Changes in Review Reports

The Editorial staff relays the comments of the reviewers on behalf of the Editor-in-Chief/Handling Editor. The review reports are edited by Editor-in-Chief/Handling Editor if the comments contain confidential information or these are written in a language not suitable for scholarly communication. Reviewers should include such comments in the confidential section of the review form, which is intended to be read by the editors only.

Conflict of Interest

Bentham Science respects requests not to have the manuscripts peer-reviewed by those experts who may have a competing interest with the author(s) of a submitted manuscript. It is not possible for Editors to be aware of all competing interests; we therefore expect that reviewers would inform the Editor-in-Chief/Handling Editor/ Publication Manager if they notice any potential competing interest during the course of review of a manuscript. Moreover, the reviewers are expected to inform the Editors or editorial office of the journal if they have a conflict of interest in carrying out a review of a manuscript submitted by any author/contributor of the manuscript.


Co-Editors tte_ce_DMGross_001 Gross Dennis M. Pennsylvania Drug Discovery Institute Doylestown PA USA Dr. Gross received a masters (M.S.) in Biology from the California State University and his doctorate (Ph.D.) in Cell Biology from the University of California, Los Angeles. He did his postdoctoral training at Tulane University School of Medicine. He has also done postgraduate programs at the Wharton School, Harvard/Tufts Law Schools and MIT. Dr. Gross is also faculty in the Jefferson College of Biomedical Sciences and the Sydney Kimmel Medical College of Thomas Jefferson University, Professor of Experimental Therapeutics and Medicinal Chemistry in the Blumberg Institute and Adjunct Professor of Basic Sciences at The Commonwealth Medical College. He has published more than 120 scientific publications. He currently is also the CEO of the Pennsylvania Drug Discovery Institute. tte_ce_CEBeyer_003 Beyer Chad E. Promentis Pharmaceuticals Milwaukee WI USA Dr. Beyer is President & CEO of Promentis Pharmaceuticals, Inc. He has nearly 20 years of experience in the research, discovery and business development of medications aimed to treat CNS and neurological disorders. Previously, Dr. Beyer served as the Head of Neurochemistry at Wyeth Pharmaceuticals in Princeton, NJ. During his career at Wyeth, Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, 3 patents, and co-edited "Next Generation Antidepressants." Dr. Beyer is also an adjunct faculty member at Thomas Jefferson University in Philadelphia where he teaches "Bioventure Management", a class focused on the business of doing science. Founding Editor tte_ce_ABReitz_002 Reitz A.B. Pennsylvania Drug Discovery Institute Doylestown PA USA Dr. Reitz obtained a doctorate (Ph.D.) in Chemistry from the University of California, San Diego. Dr. Reitz also holds an Executive Masters in Technology Management from the University of Pennsylvania (Wharton, Penn Engineering). Currently Dr. Reitz is also an Adjunct Professor in the Drexel University College of Medicine. He has published more than 150 scientific publications and is a named inventor of 60 issued U.S patents. Dr. Reitz was the founding Editor (2000) and is currently the Editor-in-Chief of this journal (Current Topics in Medicinal Chemistry, CTMC), published by Bentham Science Publishers. Associate Editors tte_ebm_steinman_031 Steinman H.A. The Wistar Institute Philadelphia PA USA Dr. Steinman holds a doctorate in biomedical sciences from the University of Massachusetts Medical School and an MBA from the university’s Isenberg School of Management. She graduated Summa Cum Laude from Baldwin-Wallace College with dual degrees in biology and psychology in the honors program. Heather Steinman, Ph.D., MBA, is Vice President for Business Development and Executive Director of Technology Transfer at The Wistar Institute, the nation’s first independent research institution devoted solely to biomedical science and a world leader in cancer, immunology, virology and infectious disease research. Dr. Steinman brings more than 18 years of experience in technology transfer and commercialization of early stage-life science discoveries. tte_ae_NLVanderford_001 Vanderford N.L. University of Kentucky Lexington KY USA Dr. Vanderford received a doctorate (Ph.D.) in Biochemistry from the University of Kentucky and he also holds a Master of Business Administration (MBA) degree. Dr. Vanderford holds a number of positions at the University of Kentucky including: Assistant Professor in the Department of Toxicology and Cancer Biology; Instructor in the Graduate School; Assistant Dean for Academic Development in the College of Medicine; and the Assistant Director for Research for the Markey Cancer Center. He has published his work in a number of prestigious journals including Science, Nature, and Nature Biotechnology. In addition to serving as Associate Editor for Technology Transfer and Entrepreneurship, he is also the Deputy Editor for the Journal of Research Administration. Section Editors tte_se_Gunn_001 Gunn M.A. University of San Francisco San Francisco CA USA Dr. Moira Gunn is an Associate Professor at University of San Francisco. She did her MS in Computer Science and PhD in Mechanical Engineering from Purdue University, Lafayette, IN, USA. Dr. Gunn has been teaching courses at the University of San Francisco since 1979. She was the Director of Information Systems Program in USF from 2007 to 2009. She is the leader of Business of Biotechnology Program in USF School of Management. She received Educator of the Year award from EE Times in 2008. She has also received Public Service Award for contribution to the public understanding of science and engineering from National Science Board in 2011. Academic Technology Transfer tte_se_JMSilvaggi_002 Silvaggi J.M. UWM Research Foundation Milwaukee WI USA Technology Transfer Dr. Jessica Silvaggi received her Ph.D. in Biochemistry from the Department of Molecular and Cellular Biology at Harvard University, and conducted a post-doctoral fellowship at the Dana Farber Cancer Institute. She has been with the UWM Research Foundation since 2009, and is currently the Senior Licensing Manager where she evaluates new inventions, manages the patent, marketing, and licensing programs, and aids in teaching students and faculty about new start-up formation. Dr. Silvaggi became a certified licensing professional in 2014, and she enjoys growing the technology transfer program at UWMRF while helping to increase the level of entrepreneurship in Milwaukee. Editorial Board Members tte_ebm_garrison-s_001 Garrison S. Aurora Research Institute Milwaukee WI USA Dr. Garrison earned his Ph.D. in Biological Sciences - Neuroscience from the University of Wisconsin, Milwaukee (USA) before completing his postdoctoral training in sensory biology at the Medical College of Wisconsin, Milwaukee (USA). He has previously worked with successful start-up companies in drug development, biotech consulting and bioinformatics. Currently, Dr. Garrison serves as a Research Scientist for the Aurora Research Institute, Aurora Health Care, and is the Wisconsin State Leader for the National Organization for Rare Disorders (NORD). tte_ebm_EBarnhard_001 Barnhard E. Leason Ellis LLP New York NY USA ELIZABETH M. BARNHARD is Chair of the Pharma/Biotech Practice Group at Leason Ellis. With her many years of pharma industry and law firm experience, she works closely with clients to create and manage robust intellectual property portfolios that add value to their businesses. She is experienced in transactional and licensing work, in all phases of litigation and appeals of patent, trademark, copyright and unfair competition actions, and in patentability, freedom-to-operate, infringement, validity, product and manufacturing patent clearances in the areas of oncology/immunology, infectious diseases, virology, central nervous system disorders, cardiovascular/metabolic disorders, and molecular genetics. tte_ebm_barrett-je_002 Barrett J.E. Drexel University College of Medicine Philadelphia PA USA Dr. James E. Barrett, Professor in the Department of Neurology, Pharmacology and Physiology and former Chair, Drexel University College of Medicine. He received his Ph.D. from Pennsylvania State University with postdoctoral training in neuropsychopharmacology at the Worcester Foundation for Experimental Biology. Dr. Barrett was Vice President of Neuroscience Discovery Research at Wyeth, Senior Vice President and Chief Scientific Officer, Adolor Corporation and Memory Pharmaceuticals. He has received several awards for significant contributions to pharmacology. He is a member of the Executive Committee of the IUPHAR. His current research emphasis is on pain and the development of novel therapeutics. tte_ebm_MGBerenstein_003 Berenstein M.G Dirección de Vinculación Tecnológica - CONICET Buenos Aires Argentina Dr Berenstein is Advisor to Vicepresident from CONICET and independent consultant in Technology transfer and Biobusiness for Scientific Community, Industry and Investment groups.. With more than 20 years of experience both in Research and tecnology transfer, she also held Management level positions in both public institutions and private companies in the Life Science Industry. She was previously ViceDirector, General Manager, and Director of leading Offices of Technology transfer and Bioincubators in Argentina (CONICET and Instituto Leloir) . Dr Berenstein holds a PhD in Gene therapy from University of Buenos Aires and an MBA from University of San Andrés. She is also Academic Director and Professor of Postgraduates courses in Pharma and Biotechnology Business from leading business Universities in Argentina. tte_ebm_AKChakraborti_005 Chakraborti A.K. National Institute of Pharmaceutical Education and Research Mohali India Dr. Asit K. Chakraborti is Professor and Head of the Department of Medicinal Chemistry, NIPER, S. A. S. Nagar, Punjab, India. He received Ph. D. degree in Synthetic Organic Chemistry from the Indian Association for the Cultivation of Science (IACS), Kolkata, India. He has published 166 research papers (with > 7600 citation and h index of 51) and filed 42 patents. He received several awards and recognition such as University Gold Medal, Bardhaman Sammilani Gold Medal, ISMAS Eminent Mass-spectroscopist Award, etc. He is the Fellow of the Royal Society of Chemistry and Indian Science Academies. tte_ebm_cullis_009 Cullis C. Case Western Reserve University Cleveland OH USA Dr. Cullis is the Francis Hobart Herrick Professor of Biology at Case Western Reserve University and Director of the Biotechnology Entrepreneurship Master’s Program. He is currently President of the Society for Bioentrepreneurship Education and Research (SIBER). His research has focused primarily on rapid genomic variation in plants. He is also currently working on developing a wild legume (marama, Tylosema esculentum) into a crop for resource poor farmers in Southern Africa. He has served as a program director at the National Science Foundation, on grant review panels, advisory and on editorial advisory boards of multiple journals. tte_ebm_KJDakin_009 Dakin K.J. Dakin Capital Services Centennial CO USA Karl Dakin has 38 years in innovation commercialization. Mr. Dakin is a respected educator, extraordinary communicator, visionary leader with an entrepreneurial spirit and a small business advocate. Mr. Dakin is engaged in multiple new product, business and economic development projects. At the crossroads of capital and food, he is leading the development of a new democratized capital ecosystem within the State of Colorado where everyone can invest in Main Street businesses and he is increasing local food production by development, sale and operation of turnkey indoor agriculture systems. tte_ebm_Lawton_001 Lawton D. Promentis Pharmaceuticals Milwaukee WI USA Daniel is President of Promentis Pharmaceuticals, Inc., a biopharma company developing new therapies for the treatment of CNS disorders. Daniel was previously Group President at Dohmen, where he led five Dohmen group companies in the life science services space. Daniel was General Counsel of Schwarz Pharma Inc. and previously at Abbott Laboratories where he was Senior Counsel to both the domestic and international organizations. Daniel is a graduate of the University of Michigan and Harvard Law School, and was a Teaching Fellow in economics at Harvard College. tte_ebm_NOssanna_022 Ossanna N. University of Arizona Tucson AZ USA Nina Ossanna, PhD holds a PhD in Molecular Biology and is a registered US patent agent. She is a founder and VP Business Development for Pharos Diagnostics and owner of Sonora Bioconsulting. She also Chairs the Bioindustry Organization of Southern Arizona. She has worked in university tech transfer directing offices at Johns Hopkins Medical School and the University of Arizona as well as working in start-up life science companies. tte_ebm_FOzsolak_023 Ozsolak F. RaNA Therapeutics Cambridge MA USA Dr. Ozsolak is an Associate Director at Vertex Pharmaceuticals. He previously worked at Biogen and RaNA Therapeutics, contributing to the discovery and development of drugs to treat CNS, liver and kidney diseases via small molecule and oligotherapeutics approaches. He obtained his PhD in biological chemistry and molecular pharmacology from Harvard University, and BA in biochemistry from Washington University in St. Louis. tte_ebm_schoen_001 Schoen F.J. Harvard Medical School Boston MA USA Frederick J. Schoen, M.D., Ph.D., is Professor of Pathology and Health Sciences and Technology (HST) at Harvard Medical School, and Executive Vice-Chairman of the Department of Pathology at Brigham and Women's Hospital (BWH). His research focuses on native and substitute heart valves. In institutional roles, he promotes multidisciplinary innovation using technology, provides mentoring and career development leadership for translational research, and teaches Pathology, Biomaterials, Tissue Engineering and Medical Device Development. He serves on the Massachusetts Life Sciences Center SAB, and many academic and governmental advisory, grant review and editorial committees, and consults with medical device companies. tte_ebm_s-m-stahl_001 Stahl S.M. University of California Oakland CA USA Dr. Stahl obtained his MD from Northwestern University, his PhD in pharmacology from the University of Chicago and his postdoctoral trainin in Internal Medicine from the University of Chicago, in Neurology from the University of California San Francisco and in Psychiatry from Stanford University. Currently Dr. Stahl is a professor of psychiatry at the University of California San Diego and an Honorary Fellow at the University of Cambridge (UK). He serves as editor-in-chief of CNS Spectrums and is director of psychopharmacology for the California Department of State Hospitals. Author of over 500 papers, 35 textbooks and 12 edited books, Dr. Stahl is an internationally recognized expert in psychopharmacology. tte_ebm_JETetzlaff_032 Tetzlaff J.E. Medical College of Wisconsin Milwaukee WI USA Dr. Tezlaff did her B.A. from University of Wisconsin-Milwaukee, Milwaukee, WI, USA; Ph.D. from Loyola University Chicago, Maywood, IL, USA; and Postdoctorate from Massachusetts General Hospital of the Harvard Medical School, Boston, MA, USA. She worked as a scientist at Seaside Therapeutics, Cambridge, MA from 2008 till 2011. In 2011, she joined Department of Pathology of the Medical College of Wisconsin and has been working there as an Assistant Professor since then. She has also been serving as the Assistant Dean of Postdoctoral Education at the Medical College of Wisconsin since 2014. Her research interest includes Sudden Infant Death Syndrome, Infant Mortality, Neuroscience, Biomarkers, Professional and career development and Entrepreneurial initiatives. tte_ebm_tobet_001 Tobet S. Colorado State University Fort Collins CO USA Dr. Tobet obtained a master’s degree (S.M.) and doctorate (Ph.D.) in Applied Biological Sciences from the Massachusetts Institute of Technology in Cambridge, MA. After 14 years in Boston as faculty at Harvard Medical School and then University of Massachusetts Medical School, he moved to Colorado State University (CSU) as a Professor in the College of Veterinary Medicine and Biomedical Sciences in 2003. In 2010 he was named the Director of the CSU School of Biomedical Engineering. He has published more than 135 papers in scientific journals. At CSU he helped create and deliver courses in Biomedical Entrepreneurship, Grant Writing, and STEM Communication.

Journal History

Technology Transfer and Entrepreneurship Journal was launched in 2014. Dr. Dennis M. Gross and Dr. Chad E. Beyer are the Co- Editors of the journal.
Track Your Manuscript:



Related Journals

Related eBooks

eBooks Catalog